Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform®
These abstracts showcase data from ImmunoID NeXT, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunoID NeXT Platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Following are details and links to the scientific posters that will be presented at the online meeting.
Poster Number, Session Category and Session Title |
Title & Presenter |
Date |
Location |
399 Clinical Research (Excluding Trials)
Biomarkers Predictive of Therapeutic Benefit |
Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS-based machine learning algorithm
Presenter:
|
|
|
555 Clinical Research (Excluding Trials)
Liquid Biopsies: Circulating DNA |
Longitudinal exome-scale liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy
Presenter: |
|
|
1898 Immunology
Antigenicity/Processing and Presentation |
Accurate modeling of antigen processing and MHC peptide presentation using large-scale immunopeptidomes and a novel machine learning framework
Presenter: |
|
|
2227 Molecular and Cellular Biology / Genetics
Genomic Profiling of Tumors |
Pan-cancer shedding patterns of tumor circulating cell free DNA
Presenter: Fábio
|
|
|
2241 Molecular and Cellular Biology / Genetics
Genomic Profiling of Tumors |
Profiling tumor-infiltrating immune cells using an augmented transcriptome
Presenter: |
|
About
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005927/en/
Investor Relations Contact for
investors@personalis.com
415-202-5678
Media Contact for
pr@personalis.com
www.personalis.com
650-752-1300
Source: